Teva and Neos settle over Cotempla patent dispute

Teva and Neos Therapeutics have reached a confidential settlement and licensing agreement that resolves a patent dispute over the Israeli firm’s generic version of Neos’ ADHD drug Cotempla XR-ODT (methylphenidate).